Skip to main content
PLOS One logoLink to PLOS One
. 2022 Aug 17;17(8):e0272857. doi: 10.1371/journal.pone.0272857

Impact of protein identity on tumor-associated antigen uptake into infiltrating immune cells: A comparison of different fluorescent proteins as model antigens

Rulan Yi 1, Emily Chen 2, Edward W Roberts 3, Matthew F Krummel 2,*, Nina Kathrin Serwas 2,*
Editor: Joseph J Barchi4
PMCID: PMC9384993  PMID: 35976946

Abstract

Effective immune responses depend on efficient antigen uptake in the periphery, transport of those antigens to, and presentation in draining lymph nodes (LNs). These processes have been studied intensively using stable fluorescent proteins (FPs) as model antigens. To date, ZsGreen is the only FP that can be tracked efficiently towards LNs, hence, it is difficult to compare studies using alternated tracking proteins. Here, we systematically compared six different FPs. We included ZsGreen, ZsYellow, DsRed, AsRed, mCherry, and mRFP based on sequence homology and/or origin species, and generated FP-expressing tumor cell lines. Stability of fluorescent signal was assessed in vitro over time, across different pH environments, and in vivo through FP antigen uptake and transfer to immune cells isolated from tumors and tumor-draining LNs. ZsGreen could be detected in high percentages of all analyzed tumor-infiltrating immune cells, with highest amounts in tumor-associated macrophages (TAMs) and type 2 conventional dendritic cells (cDC2s). ZsYellow, AsRed, and DsRed followed a similar pattern, but percentages of FP-containing immune cells in the tumor were lower than for ZsGreen. Strikingly, mRFP and mCherry demonstrated a ‘non-canonical’ antigen uptake pattern where percentages of FP-positive tumor-infiltrating immune cells were highest for cDC1s not TAMs and cDC2s despite comparable stabilities and localization of all FPs. Analysis of antigen-containing cells in the LN was hindered by intracellular degradation of FPs. Only ZsGreen could be efficiently tracked to the LN, though some signal was measurable for ZsYellow and DsRed. In summary, we find that detection of antigen uptake and distribution is subject to variabilities related to fluorophore nature. Future experiments need to consider that these processes might be impacted by protein expression, stability, or other unknown factors. Thus, our data sheds light on potential under-appreciated mechanisms regulating antigen transfer and highlights potential uses and necessary caveats to interpretation based on FP use.

Introduction

For a successful tumor immune response, the proper uptake and presentation of tumor-associated antigens (TAAs) by antigen presenting cells (APCs), such as dendritic cells (DCs), is essential. As such, antigens from peripheral tissues need to be taken up by phagocytic APCs which mature, upregulate costimulatory molecules, and present these antigens as processed peptides on MHC complexes. During this process, APCs traffic from the peripheral tissue where the tumor is located to the tumor-draining lymph node (tdLN). There, the APCs can interact with T and B cells to generate an effective long-term response [1, 2]. The interaction of the TAA-peptide:MHC complex and its accessory proteins with receptors on T and B cells determines downstream immune responses such as cell activation and differentiation. Exactly how TAAs are taken up and brought to the LN for presentation is not fully understood.

Previous studies showed that type 1 DCs (cDC1s) are essential for the transport of TAAs to the lymph node, and that this transport is dependent on C-C chemokine receptor 7 (Ccr7) [3, 4]. Upon entry into the LN, migratory DCs can transfer antigens to other lymph node resident DCs as membrane encapsulated vesicles through direct cell-cell contact [5]. The choice of the receiving DCs may then dictate the downstream immune responses generated through subsequent T cell interaction causing activation, proliferation, memory induction, and/or effector responses in the T cell [5]. Previous studies that analyzed the process of antigen uptake, presentation, and transfer have used fluorescent proteins (FPs) such as mCherry, green fluorescent protein (GFP), yellow fluorescent protein (YFP), tdTomato, and ZsGreen as model antigens [35]. FPs used in these studies seemed to have different stabilities since only ZsGreen was substantially detected in resident dendritic cells. Importantly, other tumor antigens can be tracked in those resident DCs as well, confirming that ZsGreen presence was not an artifact, but faithfully reported on transport [5]. It is not clear why other FPs cannot be transported to the same extend to the tdLNs and whether certain properties of FPs alter antigen uptake and distribution or simply degrade more rapidly than others en route to the LN.

A wide range of FPs exists that are frequently used in imaging and tracking experiments. These FPs have varying brightness and stabilities that may potentially impact the outcome of antigen uptake, transfer, and presentation. Brightness is defined as extinction coefficient times quantum yield at pH 7.4 [6] and can range from dim proteins, such as AsRed derived from Anemonia sulcate, with a brightness index of 2.81 [7], to bright proteins with indices of 90 (tdTomato) [6]. Stability is dependent on the specific environment in which the FP resides at the time of analysis [6]. In this study we tested antigen stability in vitro and in vivo for six different FPs with a range of brightness indexes between 2.81 and 49. We tracked their stabilities during uptake and intracellular storage in tumor-infiltrating immune cells and after transport to the tdLNs. The combined results offer a comprehensive overview of the properties of the chosen FPs with regards for their usefulness in assays tracking antigen uptake and transfer. This work will facilitate the choice of FPs in studies that will use two or more fluorophores in parallel.

Material and methods

Alignment

Amino acid sequences of all fluorescent proteins used were gathered via FPbase [7], then aligned via Basic Local Alignment Search Tool (BLAST) [8]. Percent similarity to ZsGreen and DsRed were determined using the global align tool.

Mice

Mice were housed and bred under specific pathogen free conditions at the University of California, San Francisco Laboratory Animal Research Center and all experiments conformed to ethical principles and guidelines approved by the UCSF Institutional Animal Care and Use Committee. C57BL/6 mice were purchased from Jackson Laboratory or bred in-house. Male mice between 8–12 weeks of age were used.

Cell lines

Vectors containing target fluorescent genes ZsGreen, ZsYellow, DsRed, AsRed, mCherry, and mRFP (Takara Bio), were either transfected into B16-F10 cells using the calcium chloride precipitation method (all FPs except ZsGreen), or retrovirally transduced into B16F10 cells (ZsGreen). Transformed cells were then harvested, washed, and repeatedly sorted through fluorescent activated cell sorting (FACS) on a BD FACSAriaTM to select for stable fluorescent positive populations. Sorted cells were then collected, frozen and/or propagated for use in future experiments. Cells were cultured at 37°C with 5% CO2 in DMEM (GIBCO) plus 10% heat-inactivated FCS with penicillin, streptomycin, and L-glutamate on tissue-culture treated plastic plates and split every other day.

Fluorescence stability assay

FP-expressing B16-F10 cells were harvested with trypsin, counted, and washed in ice cold PBS. Then, cells were homogenized with mechanical force generated through repeated passage of cells through a 22-gauge needle in hypotonic lysis buffer (20mM HEPES buffer, 2mM EGTA, 2mM MgCl2). Lysates were transferred to 96-well black microplates suitable for fluorescent based assays (Invitrogen). Each well contained lysates of 1 Mio cells. pH was adjusted with NaOH or HCl, controlled with a pH-meter before the assay, and controlled with pH-indicator strips on the lysates after the experiment to ensure that the pH was stable overtime. For each different fluorophore and pH condition, three technical replicates were performed. Data was collected over varying time points using a microplate reader (SpectraMax) and incubated at 37°C or 4C, respectively. Analysis of whole cells was done similarly in separate plates. The experiment was done in biological triplicates.

Ectopic tumor injections

B16-F10 cells expressing the respective FP were grown to 80% confluency, then harvested, washed, and counted. Cells were resuspended in a suitable amount of PBS and mixed at a 1:1 (v:v) ratio with growth factor reduced Matrigel Matrix (BD Biosciences). A final injection volume of 100ul containing 400k cells was injected subcutaneously on the flanks of mice.

Harvest, collection of data, and analysis

Tumors, inguinal and axillary lymph nodes were harvested 2 weeks after injection. After digestion with DNAse, Collagenase I and Collagenase IV, washing, and counting, 10 million cells per FP were stained with fixable Live/Dead Zombie (BioLegend) and respective antibodies: MHCII-BV421, F4/80-BV510, CD11b-BV605, CD11c-BV650, Ly6C-BV711, CD45R-BV785, CD90.2-BV785, Ly6G-BV785, NK1.1-BV785, CD8alpha-PerCPCy5.5, CD103-APC, CD45-AF700, CD24-PECy7 (Biolegend, eBioscience).

Flow cytometry was performed on a BD LSR Fortessa instrument at the ImmunoX Flow Cytometry CoLab. Analysis of flow cytometry data was done using FlowJo (Treestar) software, and graphs and figures were produced with GraphPad Prism software. All experiments were done in triplicates.

Fluorescence microscopy

Cells from each respective fluorescent cell line were thawed and cultured. 50,000 cells were seeded in a poly-L-lysine coated 8-well chambered coverslip and let rest overnight. For live cell imaging, a Leica SP5 laser scanning confocal microscope with an incubation chamber and a 20X oil objective was used to visualize adherent cells expressing respectively ZsGreen, ZsYellow, AsRed, DsRed, mRFP, and mCherry. The experiment was done in triplicates.

Results and discussion

Characteristics of selected fluorescent protein

We compared five different fluorescent proteins (FPs) for antigen uptake and transfer characteristics to ZsGreen. ZsGreen is to date the only fluorophore that can be efficiently tracked from expressing tumors to lymph node resident dendritic cells. Our selection (Table 1) was based on species origin (ZsYellow), brightness of the fluorophore (DsRed), sequence homology (mCherry, mRFP) and availability of corresponding biochemical tools (AsRed, mRFP, mCherry). ZsGreen, is derived from corals of the Zoanthus sp, and has been shown to have high stability in various chemical environments [9]. Its brightness index is 22.43 [7]. ZsYellow is a stable protein purified from the same species as ZsGreen, and is excited at a wavelength around 528 nm with a brightness index of 13 [7, 9]. DsRed is derived from Discosoma sp [10], excited by a wavelength of 558 nm, and has a brightness index of 49.3 [7]. Naturally occurring FPs such as DsRed have been modified to achieve proteins with optimized brightness and stability properties such as mRFP and mCherry, with brightness indices of 12.5 and 15.84 respectively [7]. In addition, these modified proteins exist as monomers in contrast to the tetrameric nature of ZsGreen and DsRed [7]. AsRed has the lowest brightness in our collection (2.81) and is expressed in the coral species Anemonia sulcate [6, 7, 10].

Table 1. Fluorophore properties [7, 8].

Fluorophore Brightness Excitation Emission % similarity to ZsGreen % similarity to DsRed
AsRed 2.81 576 nm 592 nm 53.78% 61.54%
mRFP 12.5 584 nm 607 nm 56.65% 87.56%
ZsYellow 13 528 nm 539 nm 91.77% 58.87%
mCherry 15.84 587 nm 610 nm 53.53% 82.63%
ZsGreen 22.43 496 nm 506 nm 59.23%
DsRed 49.3 558 nm 583 nm 59.23%

Summary of used fluorophores and their respective similarity with ZsGreen and DsRed [7, 8]

FP-encoding vectors were transfected or transduced into B16-F10 cell lines. Transformed cells with the highest signal for the respective FP were repeatedly sorted with a 5%- cut-off using fluorescence activated cell sorting (FACS) (Fig 1A and 1B). All generated cell lines reached high FP positivity with a 2–3 log fluorescent intensity difference over un-transformed cells (Fig 1A and 1B). Despite repeated and stringent selection for FP-positivity, both ZsYellow- and mCherry-transfected B16-F10 cells kept a substantial amount of non-fluorescent cells in their cultures (Fig 1B). This might be due to non-stable integration or epigenetic silencing of the transgene. In subsequent analyses we considered this bimodal distribution as a potential factor for differences in antigen uptake or distribution. Previous work has shown that differential subcellular localization has an effect on antigen uptake and distribution into compartments of the immune system [11]. All generated cell lines had their respective FPs evenly distributed in the cytoplasm (S1 Fig).

Fig 1. Generation of cell lines with respective fluorescent genes for downstream analysis.

Fig 1

A) Retroviral vectors expressing respective fluorescent genes ZsGreen, ZsYellow, mCherry, mRFP, DsRed, and AsRed were transfected/transduced into B16-10 cells. B) Fluorescence-activated cell sorting (FACS) was then used to select for FP positivity. ZsYellow and mCherry cells display a bimodal pattern despite undergoing FACS multiple times with a selection criterion for the top 5% of FP positive cells. Histograms are shown with % positive cells and average mean fluorescence intensity of the chosen fluorophore (+/- standard deviation).

Assessment of in vitro stability

The stability of fluorophores expressed in the generated cell lines was assessed in an in vitro fluorescent stability assay. For this purpose, FP-expressing B16-F10 cell lines were lysed in a hypotonic lysis buffer. Lysates were then kept at 37°C to mimic the cellular environment. No protease inhibitors were added. This allowed us to follow protein stability in the cytosolic soup containing various proteases and other enzymes, through fluorescence intensity, over time. As this assay investigates the stability of FPs, and not their individual brightness, we internally normalized the brightness to timepoint 0 in neutral pH conditions. In general, ZsGreen demonstrated the highest stability of all analyzed FPs, and showed only a minimal decrease in fluorescent signal over the time frame of 6 hours (Fig 2A). This high stability of ZsGreen is in concordance to previous published work [9]. In contrast, all other FPs showed a severe reduction of signal over the first two hours (Fig 2A). Acidification of the protein lysates showed relative robustness of all FPs to pH alterations (Fig 2B). The highest fluorescent intensity of all FPs could be detected at neutral pH conditions which is in line with previous published analyses of pH stability for fluorescent proteins [12]. Our data suggests that the impact of acidification in certain intracellular compartments only plays a minimal role on FP fluorescence intensity and stability. However, proteins might be degraded over time through intracellular proteases or other enzymes, which was especially true for ZsYellow, AsRed, DsRed, mRFP, and mCherry. ZsGreen markedly showed resistance towards degradation by proteins contained in the cellular lysates which might explain its superior performance in tumor-associated antigen tracking experiments. Differences between FPs other than ZsGreen in those assays seem to not be caused by different fluorescence stabilities.

Fig 2. In vitro stability assay shows comparable stabilities of selected fluorophores.

Fig 2

Lysates of 1 million respective FP-expressing B16-F10 cells were generated in hypotonic lysis buffer and incubated at A) 37°C in pH 7.4 or B) 37°C in pH ranging from 5–7.4. Fluorescence intensity data was collected over time at the indicated time points (A) or immediately following pH treatment (B). Data was normalized to the maximum fluorescence intensity of each FP for every independent experiment.

Tumor-associated antigen uptake varies for different FPs

To evaluate tumor-associated antigen (TAA) uptake of the six selected FPs, cells were injected bilaterally into the flanks of B6 mice (Fig 3A). Tumors averaged a size of 1300 mm3 for all FP-containing cell lines two weeks after inocculation (Fig 3B). None of the generated FP-expressing B16-F10 cell lines resulted in severe increase or reduction of tumor growth, suggesting that the modification did not alter proliferation or fitness of the cells. For antigen tracking analysis, only tumors of a size equal to or greater than 800 mm3 were included.

Fig 3. Growth and harvest of respective fluorescent cell lines.

Fig 3

A) Fluorescent cell lines were grown, harvested, and injected subcutaneously on the flanks of B6 mice. After 14 days, tumors and draining lymph nodes were harvested and processed for flow cytometry. B) Average sizes of tumors (mm3) at harvest are shown for all six respective fluorophores. Size was controlled to ensure comparable in vivo growth of different FP-expressing B16-F10 cell lines.

We assessed distribution of FPs into different cellular populations of the tumor, namely monocytes, neutrophils, tumor associated macrophages (TAMs), and DCs (Fig 4 and S2 Fig). Of note, infiltrating immune cell composition were similar for all injected tumors (S3 Fig). Among the selected FPs, percentages of FP-containing immune cells were highest in tumors expressing ZsGreen. Interestingly, we identified two distinct antigen uptake pattern: The ‘classical’ pattern showed highest percentages of FP-containing cells for cDC2s, TAM1s, and TAM2s. ZsGreen-expressing tumor cells resulted in nearly 100% of these infiltrating immune cells to contain the FP. ZsYellow-, DsRed- and AsRed-expressing tumor cells resulted in less FP-positive immune cells, however, cDC2s, and TAMs were still the prime samplers of tumor associated FPs. For this ‘classical’ uptake pattern, a smaller fraction of neutrophils, monocytes, and cDC1s displayed FP signal than seen for cDC2s and TAMs. The ‘non-canonical’ antigen uptake pattern was characterized by highest proportions of FP-positive cells for cDC1s and not cDC2s or TAMs. Also for this pattern, the lowest amount of transferred antigen could be seen in neutrophils and monocytes. Both, mRFP- and mCherry-expressing tumors resulted in such a distinct pattern of FP uptake by immune cells (Fig 4). Despite comparable brightness, mCherry resulted in overall higher percentages of FP-positive tumor-infiltrating immune cells than mRFP (Fig 4). Remarkably, this was true although mCherry-expressing cells were a mixture of only two thirds transformed and one third WT cells (Fig 1B).

Fig 4. TAA uptake by tumor-infiltrating immune cells identifies different patterns for different fluorophores.

Fig 4

Accumulation of respective fluorescent proteins in immune cells, purified from the tumor microenvironment. A non-fluorescent control (B16-F10) was used to set the threshold for FP positivity. One representative example of three independent experiments is shown.

Next, we analyzed the average amount of FPs within each of the individual populations. We used normalized delta mean fluorescence intensity to visualize how much sampled FP each cell population contained in comparison to other immune cells sampling from the same fluorophore. Overall patterns of relative uptake per cell (Fig 5) showed more similarity than the percentages of FP- positive cells (Fig 4). For most of the tumors, cDC2s and TAMs were the cells that contained most FP. The only exception from this was mRFP containing neutrophils which on average contained more FP than TAM2s. Despite showing a ‘non-canonical’ uptake pattern, cDC1s infiltrating mRFP and mCherry-expressing tumors did not contain an increased amount of antigen.

Fig 5. cDC2s and TAMs contain the most fluorescent TAAs per individual cell.

Fig 5

Immune cells were purified from the TME of B16 mice bearing B16 tumors with the indicated fluorophors and analyzed for relative antigen uptake. Data was normalized to the maximum delta MFI of each FP for every independent experiment.

It remains unclear what causes the increased percentage of FP-positive tumor infiltrating cDC1s in mRFP and mCherry-expressing tumors. Numbers of cDC1s are not different between tumors expressing FPs irrespectively of whether they cause ‘classical’ or ‘non-canonical’ antigen uptake patterns (S3 Fig). Of note, whereas ZsGreen, ZsYellow, AsRed, and DsRed are proteins directly isolated from distinct organism, mCherry and mRFP have been designed to better serve as tools for molecular biology. Changes aimed to enhance brightness and stability, and to prevent dimerization [10, 13].

ZsGreen, ZsYellow, and DsRed can be tracked in the tdLN

All investigated FPs could be detected in tumor-infiltrating immune cells to a certain extend when expressed in injected B16-F10 tumor cells. Next, we wanted to determine whether selected fluorophores remained intact after trafficking of the containing immune cells to tumor-draining lymph nodes (tdLN). We isolated these lymph nodes and analyzed migratory and resident DCs as well as monocytes by flow cytometry. Migratory DCs, monocytes, and neutrophils can transport antigens to the draining LN in a Ccr7-dependent manner [3, 14, 15]. Resident DCs can receive those antigens through synaptic transfer [5].

Analysis of lymph nodes harvested from mice injected with B16-ZsGreen tumor cells revealed FP signal in both, migratory and resident DCs, as well as in monocytes. Almost 90% of monocytes, 10–20% of cDC1s, and up to 50% of cDC2s had detectable ZsGreen inside them (Fig 6 and S4 Fig). Other FPs showed only a limited signal suggesting that proteins could have already been degraded on their way to the draining lymph node, perhaps due to shuttling of the FPs into a different intracellular environment or organelle. Percentages of ZsYellow and DsRed positive immune cells in respective tdLNs where with up to 20% highest in cDC2s and monocytes, but severly lower than what has been seen for ZsGreen expressing tumors. Fluorescent signal in cDC1s was barely detectable. No signal could be detected in tdLN from mice injected with B16 tumors expressing AsRed, mRFP and mCherry. Interestingly, previous reports showed that mCherry signal could be detected in tdLNs [3]. This difference might be due to different tumor models, different tumor sizes at harvest, and/or the mixture of wild type and mCherry expressing cells in our cell line (Fig 1B).

Fig 6. Limited detection of other non-ZsGreen fluorescent proteins within immune cells of tumor draining lymph nodes.

Fig 6

Tumor draining (inguinal and axillary) lymph nodes were harvested, processed, and analyzed through flow cytometry. Non-fluorescent control (B16-F10) was used to set the threshold for FP positivity. One representative example of three independent experiments is shown.

In summary, ZsGreen was the only FP of the diverse groups of FPs tested that could be tracked efficiently to the tdLN. ZsYellow and DsRed showed significantly less FP signal in immune cells of the tdLN, but could still be considered as potential tools to analyze TAA transfer between immune cells in tdLNs.

Conclusion

In summary, we tested six FPs: ZsGreen, ZsYellow, AsRed, DsRed, mRFP, and mCherry using an antigen uptake and transfer model. Despite comparable in vitro stabilities, those FPs showed vastly different loading patterns into tumor-infiltrating immune cells. ZsGreen is the only FP that can be efficiently tracked in lymph node resident DCs and remains the FP to be considered best for use in antigen uptake and transfer assays. We identified ZsYellow and DsRed as additional useful tools for these assays, however, tracking was not as efficient and consistent as for ZsGreen and might need optimization. Additionally, we identified two distinct patterns of FP-antigen loading into tumor-infiltrating immune cells. The ‘classical’ pattern showed preferential uptake of FPs by cDC2s and TAMs, whereas the ‘non-canonical’ pattern revealed highest antigen signal in tumor-infiltrating cDC1s. The underlying mechanisms for these distinct antigen uptake patterns remain elusive. Our data suggests that analyses of antigen uptake and transfer using different FPs should be carried out only after careful consideration of FP uptake patterns. Potential differences might arise as a result of the nature of the chosen FPs.

Supporting information

S1 Fig. Similar subcellular localization of fluorescent proteins in FP-expressing B16-F10 cell lines.

Generated B16 melanoma cells with expression of fluorescent protein ZsGreen (A), ZsYellow (B), AsRed, DsRed, mRFP, and mCherry (all C) respectively, overlayed with their bright field images. Images of B16-F10 cell lines were taken to set background fluorescence.

(TIF)

S2 Fig. Gating scheme for flow cytometry analysis of tumor and lymph node samples.

A) Cells collected from tumors were analyzed by flow cytometry using the shown gating methods. Percentages of FP positive cells were analyzed in cDC1, cDC2, TAM1, TAM2, monocytes and neutrophils. B) Lymph node cells were analyzed using these gating methods. The dump- populations are B220, CD 90.2, NK 1.1 lineage marker negative cells. Percentage of FP positive cells were analyzed in migratory cDC1, migratory cDC2, resident cDC1, resident cDC2 and monocytes.

(TIF)

S3 Fig. Tumor cell population distributions.

All tumor cells collected were analyzed for their respective immune cell markers. The cell count for each type of immune cell is then plotted as percentages over the total number of live CD45+ cells.

(TIF)

S4 Fig. Lymph node cell population distributions.

All lymph node cells collected were analyzed for their respective immune cell markers. The cell count for each type of immune cell is then plotted as percentages over the total number of live CD45+ cells.

(TIF)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by Human Frontier Science Program in the form of a fellowship (LT000061/2018-L) to NKS. This work was also supported by National Institutes of Health in the form of a grant (5U01CA217864) to MFK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, et al. Dendritic cell biology and its role in tumor immunotherapy. Journal of Hematology and Oncology. 2020;13. doi: 10.1186/s13045-020-00939-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dersh D, Hollý J, Yewdell JW. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nature Reviews Immunology. 2021;21: 116–128. doi: 10.1038/s41577-020-0390-6 [DOI] [PubMed] [Google Scholar]
  • 3.Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016/07/19. 2016;30: 324–336. Available: http://www.ncbi.nlm.nih.gov/pubmed/27424807 doi: 10.1016/j.ccell.2016.06.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016;44: 924–938. doi: 10.1016/j.immuni.2016.03.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ruhland MK, Roberts EW, Cai E, Mujal AM, Marchuk K, Beppler C, et al. Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells. Cancer Cell. 2020;37: 786–799. doi: 10.1016/j.ccell.2020.05.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Shaner NC, Steinbach PA, Tsien RY. A guide to choosing fluorescent proteins. Nature Methods. 2005;2: 905–909. doi: 10.1038/nmeth819 [DOI] [PubMed] [Google Scholar]
  • 7.Lambert TJ. FPbase: a community-editable fluorescent protein database. Nature Methods. 2019;16: 277–278. doi: 10.1038/s41592-019-0352-8 [DOI] [PubMed] [Google Scholar]
  • 8.Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. Journal of Molecular Biology. 1990;215: 403–410. doi: 10.1016/S0022-2836(05)80360-2 [DOI] [PubMed] [Google Scholar]
  • 9.Matz M V., Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML, et al. Fluorescent proteins from nonbioluminescent Anthozoa species. Nature Biotechnology. 1999;17: 969–973. doi: 10.1038/13657 [DOI] [PubMed] [Google Scholar]
  • 10.Shaner NC, Campbell RE, Steinbach PA, Giepmans BNG, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nature Biotechnology. 2004;22: 1567–1572. doi: 10.1038/nbt1037 [DOI] [PubMed] [Google Scholar]
  • 11.Babała N, Bovens A, De Vries E, Iglesias-Guimarais V, Ahrends T, Krummel MF, et al. Subcellular localization of antigen in keratinocytes dictates delivery of CD4 þ T-cell Help for the CTL response upon therapeutic DNA vaccination into the Skin. Cancer Immunology Research. 2018;6: 835–847. doi: 10.1158/2326-6066.CIR-17-0408 [DOI] [PubMed] [Google Scholar]
  • 12.Shinoda H, Shannon M, Nagai T. Fluorescent proteins for investigating biological events in acidic environments. International Journal of Molecular Sciences. 2018;19. doi: 10.3390/ijms19061548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A. 2002;99: 7877–7882. doi: 10.1073/pnas.082243699 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJM, Tanguy M, et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood. 2005;106: 1843–1850. doi: 10.1182/blood-2005-03-1281 [DOI] [PubMed] [Google Scholar]
  • 15.Özcan A, Collado-Diaz V, Egholm C, Tomura M, Gunzer M, Halin C, et al. CCR7-guided neutrophil redirection to skin-draining lymph nodes regulates cutaneous inflammation and infection. Science Immunology. 2022;7: 9126. doi: 10.1126/sciimmunol.abi9126 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Joseph J Barchi

18 Mar 2022

PONE-D-21-35588Impact of Protein Identity on Tumor-Associated Antigen Uptake into Infiltrating Immune Cells: A Comparison of Different Fluorescent Proteins as Model AntigensPLOS ONE

Dear Dr. Serwas,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

First, please accept my apologies for the delay, as it was very difficult finding appropriate reviewers.  As you can see, Reviewer #1 was very supportive while reviewer #2 was not as positive. I suggest you address the comments of reviewer #2 and I will happily consider publication of a revised manuscript. If you feel additional experiments are not warranted, please be as comprehensive as possible in describing your reasoning in your response.   Please ensure that your decision is justified on PLOS ONE’s publication criteria and not, for example, on novelty or perceived impact.

For Lab, Study and Registered Report Protocols: These article types are not expected to include results but may include pilot data. 

==============================

Please submit your revised manuscript by May 02 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Joseph J Barchi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please update your submission to use the PLOS LaTeX template. The template and more information on our requirements for LaTeX submissions can be found at http://journals.plos.org/plosone/s/latex.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Summary: In their report, Serwas et al. conduct a systematic head-on comparison of six fluorescent proteins with a variety of optical features, for their ability to be employed for tumor-assisted antigen uptake studies. While a range of prior reports have independently evaluated these features and unanimously suggested the benefits of ZsGreen, their head-on comparison is unprecedented. This study is important in assisting the choice of the right fluorescent protein depending on the type of study being conducted. The authors report the generation of cell lines with the six fluorescent genes, followed by the evaluation of their in vitro stability. Eventually the genetically modified cell lines are introduced in vivo, and the tumors and the tumor draining lymph nodes are harvested and evaluated for the immune cell population using flow cytometry.

Review:

The paper is scientifically sound and thoughtfully presented. The observation of two different patterns of fluorescent protein-antigen loading in the cells infiltrating the tumors is interesting while the mechanism remains unknown. Notably, all the fluorescent proteins show a similarity in the relative excess of the tumor-associated antigens in cDC2, and tumor associated macrophages. The experimental work is well done and presented clearly, with the authors highlighting the limitations and proposing the potential alternatives. This novel study opens interesting perspectives for the choice of fluorescent proteins for studying specific antigen uptake pattern. The authors do a good job on reporting the experimental outcomes and logistically address the pros/cons of each evaluated protein. The reviewer particularly appreciates the discussion of the methodology used for gating in flow cytometry section. This is a good practice and is hopefully normalized. The referencing is appropriate and well-formatted. I recommend its publication in PLOS One in its current form.

Minor comments:

1. The authors need to confirm if the mode of transfection was through retroviral or lentiviral. There seems to be a discrepancy in the text and figure legend.

2. The authors are encouraged to fix the minor typos in the document.

3. The authors allude to the possibility of certain fluorescent proteins degrading prior to being up taken in the lymph nodes. However, the reviewer wonders if this could this also be seen as a function of the changes in fluorescence in the variety of environments they are exposed to.

Reviewer #2: In this manuscript, authors systematically compared six different fluorescent proteins, namely ZsGreen, ZsYellow, DsRed, AsRed, mCherry, and mRFP. Stability of fluorescent signal was assessed in vitro over time, across different pH environments, and in vivo through FP antigen uptake and transfer to immune cells isolated from tumors and tumor-draining LNs. The mechanism of this process is unclear, which made the paper is not comprehensive and convincing. It is reasonable to conduct computational simulation and simply structure alignment to investigate the antigen uptake of those FPs.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Siddharth Sai Matikonda

Reviewer #2: Yes: Yanting Xing

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Aug 17;17(8):e0272857. doi: 10.1371/journal.pone.0272857.r002

Author response to Decision Letter 0


18 May 2022

Thank you all very much for your time and enthusiasm for the data and the conclusions we presented. We find your comments very helpful to provide us a path toward publication in PLOS ONE. Below you will find detailed responses to the reviewer comments.

We want to mention that we also added two additional references which are not responses to reviewers. Since the initial submission in November 2021, a new paper showed that neutrophils can transport bacterial antigens to the lymph nodes in a Ccr7-dependent manner (Özcan et al., Science Immunology (2022), 9126, 7(68)). We think this piece of information is important as the study that we cite for the transport of tumor antigens to the lymph node did not completely rule out neutrophils as a possible transport vehicle. Hence, we modified the text and included the above-mentioned citation and the original citation showing transport of bacterial antigens to the lymph nodes:

“…Migratory DCs, and monocytes, and neutrophils are canresponsible for the transport of tumor-associated antigens to the draining tdLN in a Ccr7-dependent manner [3,14,15]., whereas r Resident DCs can receive those antigens through synaptic transfer [5].

Reviewer’s comments

Reviewer #1:

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

5. Review Comments to the Author

Reviewer #1: Summary: In their report, Serwas et al. conduct a systematic head-on comparison of six fluorescent proteins with a variety of optical features, for their ability to be employed for tumor-assisted antigen uptake studies. While a range of prior reports have independently evaluated these features and unanimously suggested the benefits of ZsGreen, their head-on comparison is unprecedented. This study is important in assisting the choice of the right fluorescent protein depending on the type of study being conducted. The authors report the generation of cell lines with the six fluorescent genes, followed by the evaluation of their in vitro stability. Eventually the genetically modified cell lines are introduced in vivo, and the tumors and the tumor draining lymph nodes are harvested and evaluated for the immune cell population using flow cytometry.

Review:

The paper is scientifically sound and thoughtfully presented. The observation of two different patterns of fluorescent protein-antigen loading in the cells infiltrating the tumors is interesting while the mechanism remains unknown. Notably, all the fluorescent proteins show a similarity in the relative excess of the tumor-associated antigens in cDC2, and tumor associated macrophages. The experimental work is well done and presented clearly, with the authors highlighting the limitations and proposing the potential alternatives. This novel study opens interesting perspectives for the choice of fluorescent proteins for studying specific antigen uptake pattern. The authors do a good job on reporting the experimental outcomes and logistically address the pros/cons of each evaluated protein. The reviewer particularly appreciates the discussion of the methodology used for gating in flow cytometry section. This is a good practice and is hopefully normalized. The referencing is appropriate and well-formatted. I recommend its publication in PLOS One in its current form.

We thank the reviewer for the positive comments on our manuscript.

Minor comments:

1. The authors need to confirm if the mode of transfection was through retroviral or lentiviral. There seems to be a discrepancy in the text and figure legend.

Thank you for noticing this. The mode of transfection was indeed retroviral, and we changed that accordingly. We also took the chance to assess the correct use of the terms transduction and transfection and correct the language were needed.

2. The authors are encouraged to fix the minor typos in the document.

We have had multiple proof-reading sessions and believe that we have found and corrected all remaining typos.

3. The authors allude to the possibility of certain fluorescent proteins degrading prior to being up taken in the lymph nodes. However, the reviewer wonders if this could also be seen as a function of the changes in fluorescence in the variety of environments they are exposed to.

In theory, the different fluorescent proteins (FPs) should all experience a similar intracellular environment. However, our data shows that there are substantial differences of protein uptake and maintenance dependent on protein identity. Thus, it might indeed be possible that the FPs are shuttled into distinct organelles, and hence, experience a different intracellular environment. We included a short sentence referring to that possibility in our manuscript:

“…Other FPs showed only a limited signal suggesting that proteins could have already been degraded on their way to the draining lymph node, perhaps due to shuttling of the FPs into a different intracellular environment or organelle…”

Reviewer #2:

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #2: Partly

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #2: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #2: Yes

5. Review Comments to the Author

Reviewer #2: In this manuscript, authors systematically compared six different fluorescent proteins, namely ZsGreen, ZsYellow, DsRed, AsRed, mCherry, and mRFP. Stability of fluorescent signal was assessed in vitro over time, across different pH environments, and in vivo through FP antigen uptake and transfer to immune cells isolated from tumors and tumor draining LNs. The mechanism of this process is unclear, which made the paper is not comprehensive and convincing. It is reasonable to conduct computational simulation and simply structure alignment to investigate the antigen uptake of those FPs.

We thank the reviewer for critically assessing the quality of our study. We agree with the reviewer that the underlying mechanisms for transfer of FPs, or more generally speaking tumor-associated antigens, to immune cells is not well understood. Previous work suggest that myeloid cells engulf dying tumor cells and ingest them before preparing containing proteins for presentation on their immune cells (Broz et al., Cancer Cell (2014), 638-52, 26(5); Salmon et al., Immunity (2016), 924-38, 44(4); Maier et al., Nature (2020), 257-62, 580(7802)). However, there are a multitude of ways how particles can be ingested into cells (Kumari et al., (2010), 256-75, 20(3)).

The exact consequences of the mode of transfer are not well understood but might be potentially important to determine the elicited immune response. As such we demonstrated in previous work that transferred tumor antigen can be traded among immune cells in the draining lymph nodes (Ruhland et al., Cancer Cell (2020), 786-799, 37(6)). To fully elucidate the underlying mechanism of transfer, and to define consequences of antigen transfer, it is tremendously important to choose the right model antigen. We believe our paper will assist researchers to make the right choice of fluorescent protein. Our findings are important to consider when choosing model antigens for the analysis of antigen uptake and transfer.

The reviewer requests us to undertake a crystallography study:

For us, it is not clear how simple structure alignment and computational simulations should elucidate the mechanism of differential antigen transfer. Only 3 of the chosen fluorescent proteins have available 3D structures on the protein data bank, namely ZsGreen, DsRed and mCherry. The protein structure of fluorescent proteins is quite conserved, so it is not surprising that simple structure alignments with the Matchmaker tool of UCSF ChimeraX (Pettersen et al., Protein Science (2021), 70-82, 30 (1)) result in a substantial overlap of the structures (see Reviewer Figure 1 in the Response to Reviewer document). However, the entire understanding of what will make these structures more or less labile is complex and, we feel, well beyond the goal of this publication which is intended to highlight important differences.

At the highest level of abstraction, the main difference between these chosen proteins is the tendency to form dimers, tetramers, or remain as monomers. It is not clear whether these changes result in different antigen transfer, uptake, and/or maintenance, but could be a possibility. We added a sentence, and a corresponding reference, reflecting the different tendencies for multimerization of the proteins into our manuscript:

“…It remains unclear what causes the increased percentage of FP-positive tumor infiltrating cDC1s in mRFP and mCherry-expressing tumors. Numbers of cDC1s are not different between tumors expressing FPs irrespectively of whether they cause ‘classical’ or ‘non-canonical’ antigen uptake patterns (S3 Fig). Of note, whereas ZsGreen, ZsYellow, AsRed, and DsRed are proteins directly isolated from distinct organism, mCherry and mRFP have been designed to better serve as tools for molecular biology. Changes aimed to enhance brightness and stability, and to prevent dimerization [10,13]. ...”

Attachment

Submitted filename: Reponse to Reviewers.pdf

Decision Letter 1

Joseph J Barchi

28 Jul 2022

Impact of Protein Identity on Tumor-Associated Antigen Uptake into Infiltrating Immune Cells: A Comparison of Different Fluorescent Proteins as Model Antigens

PONE-D-21-35588R1

Dear Dr. Serwas,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Joseph J Barchi

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Yanting Xing

**********

Acceptance letter

Joseph J Barchi

9 Aug 2022

PONE-D-21-35588R1

Impact of Protein Identity on Tumor-Associated Antigen Uptake into Infiltrating Immune Cells: A Comparison of Different Fluorescent Proteins as Model Antigens

Dear Dr. Serwas:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Joseph J Barchi

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Similar subcellular localization of fluorescent proteins in FP-expressing B16-F10 cell lines.

    Generated B16 melanoma cells with expression of fluorescent protein ZsGreen (A), ZsYellow (B), AsRed, DsRed, mRFP, and mCherry (all C) respectively, overlayed with their bright field images. Images of B16-F10 cell lines were taken to set background fluorescence.

    (TIF)

    S2 Fig. Gating scheme for flow cytometry analysis of tumor and lymph node samples.

    A) Cells collected from tumors were analyzed by flow cytometry using the shown gating methods. Percentages of FP positive cells were analyzed in cDC1, cDC2, TAM1, TAM2, monocytes and neutrophils. B) Lymph node cells were analyzed using these gating methods. The dump- populations are B220, CD 90.2, NK 1.1 lineage marker negative cells. Percentage of FP positive cells were analyzed in migratory cDC1, migratory cDC2, resident cDC1, resident cDC2 and monocytes.

    (TIF)

    S3 Fig. Tumor cell population distributions.

    All tumor cells collected were analyzed for their respective immune cell markers. The cell count for each type of immune cell is then plotted as percentages over the total number of live CD45+ cells.

    (TIF)

    S4 Fig. Lymph node cell population distributions.

    All lymph node cells collected were analyzed for their respective immune cell markers. The cell count for each type of immune cell is then plotted as percentages over the total number of live CD45+ cells.

    (TIF)

    Attachment

    Submitted filename: Reponse to Reviewers.pdf

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES